Advancing Medicines for Hormone Driven Cancers
Hormone receptor positive (HR+) cancers, including ovarian, endometrial (uterine), and breast result in over 75,000 deaths per year in the United States. Antihormonals and chemotherapies are still the most common therapies used to treat these cancers. There is a need for new therapies with improved efficacy and tolerability.
Rare Gynecological Cancers
Ovarian and endometrial cancers are comprised of several subtypes based on biophysical and molecular determinants. Subtypes that respond to progesterone signaling are typically rare and are often associated with worse prognosis.
Context Therapeutics and Wisconsin Oncology Network (WON) to Evaluate Apristor Combination Therapy for Women with A… https://t.co/QkihNCu9oI
Context Therapeutics and SOLTI launch ONAWA: a Window of Opportunity Study in Breast Cancer with Apristor